Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

Malta - English - Medicines Authority

espl regulatory consulting ltd - mesalazine - modified-release tablet - mesalazine 1600 milligram(s) - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Israel - English - Ministry of Health

tradis gat ltd - mesalazine - tablets enteric coated - mesalazine 800 mg - mesalazine - mesalazine - ulcerative colitis:-for the treatment of mild to moderate acute exacerbations. -for the maintenance of remission.crohn's disease:-for the treatment of acute episodes.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - mesalazine - tablets slow release - mesalazine 1 g - mesalazine - mesalazine - mild to moderate ulcerative colitis. crohn's disease.

Israel - English - Ministry of Health

tradis gat ltd - mesalazine - tablets enteric coated - mesalazine 400 mg - mesalazine - mesalazine - ulcerative colitis:-for the treatment of mild to moderate acute exacerbations. -for the maintenance of remission.crohn's disease:-for the treatment of acute episodes.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - mesalazine - tablets slow release - mesalazine 500 mg - mesalazine - mesalazine - mild to moderate ulcerative colitis.crohn's disease

Ireland - English - HPRA (Health Products Regulatory Authority)

espl regulatory consulting limited - mesalazine - modified-release tablets - 1600 milligram - aminosalicylic acid and similar agents

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 3000 mg - granules, modified release - excipient ingredients: aspartame; carmellose sodium; microcrystalline cellulose; citric acid; hypromellose; magnesium stearate; methylcellulose; povidone; colloidal anhydrous silica; simethicone; sorbic acid; purified talc; titanium dioxide; triethyl citrate; methacrylic acid copolymer; flavour - salofalk granules granules are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1500 mg - granules, modified release - excipient ingredients: sorbic acid; magnesium stearate; triethyl citrate; hypromellose; methylcellulose; aspartame; povidone; purified talc; microcrystalline cellulose; methacrylic acid copolymer; carmellose sodium; simethicone; citric acid; colloidal anhydrous silica; titanium dioxide; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: sodium carbonate; glycine; povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000; basic butylated methacrylate copolymer - salofalk granules and tablets are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis. treatment of acute episodes and maintenance of remission of crohn's ileitis and colitis.